BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 14, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» ONCR-GBM proves to be efficacious in preclinical studies of glioblastoma
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
ONCR-GBM proves to be efficacious in preclinical studies of glioblastoma
Nov. 24, 2022
No Comments
Glioblastoma (GBM) is the most common type of primary brain tumor in adults, with only a 7% rate of 5-year overall survival for patients. Oncolytic viruses based on HSV-1 vectors are an interesting and to-explore area for GBM treatment.
BioWorld Science
Conferences
Cancer
Immuno-oncology